Parallel Advisors’s Niagen Bioscience NAGE Stock Holding History

Parallel Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-100	Closed	-$1K	–	3303
2021 Q2	$1K	Buy	+100	New	+$872	﹤0.01%	2863

Other funds holding NAGE

YRHAM

Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parallel Advisors's NAGE Position: Q3 2021 in Review

Parallel Advisors sold out of Niagen Bioscience (NAGE) in Q3 2021, closing a stake of 100 shares — an estimated $1K sold.

Parallel Advisors first reported a position in NAGE in Q2 2021 and held it in 1 quarter. The position peaked at $1K in Q2 2021. 86 funds tracked by Wall St. Rank hold NAGE as of Q3 2021.

Parallel Advisors reported no remaining Niagen Bioscience position as of Q3 2021 after selling out during the quarter.
Parallel Advisors sold 100 Niagen Bioscience shares in Q3 2021, an estimated $1K.
Parallel Advisors first reported a position in Niagen Bioscience in Q2 2021 and held it in 1 quarter.
Parallel Advisors's Niagen Bioscience position peaked at $1K in Q2 2021.
86 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2021.

Based on Parallel Advisors's 13F filing for Q3 2021, filed 22 Oct 2021.